Virtual reality-based cognitive rehabilitation programme to support employment in patients with breast cancer: protocol for the Cog-RV pilot study Authors: Ilona Vieira Jales, Emilie Hummel, Bénédicte Clarisse, Valérie Gouranton, Mélanie Cogné, Anatole Lecuyer, Alexandra Leconte, Justine Lequesne, Djihane Ahmed-Lecheheb, Adeline Morel, Marie Fernette, Florence Joly, Marie Lange Published: 2025 ABSTRACT AbstractIntroductionCancer-related cognitive impairment is frequently reported by patients with breast cancer after chemotherapy. These difficulties can hinder return to work. It is therefore particularly important to assess and manage these impairments, especially to facilitate employment. We propose the Cog-VR pilot study to assess patient adherence to a virtual reality (VR)-based cognitive rehabilitation programme to support employment.Methods and analysisThis prospective interventional pilot study aims to assess adherence to a VR-based cognitive rehabilitation programme in patients with breast cancer (n=23) treated by chemotherapy reporting cognitive complaints following cancer and its treatments. The programme consists of six weekly individual sessions (1 hour/week), including cognitive training, psychoeducation and VR immersion (10–15 min). VR tasks train executive functions, attention, memory and processing speed. The primary endpoint is the programme adherence, defined as completing at least five out of six VR sessions, each lasting a minimum of 5 min. The main secondary endpoints are objective cognitive tests and patient-reported outcomes (subjective cognitive functioning (Functional Assessment of Cancer Therapy—Cognitive Scale), anxiety/depression (Hospital Anxiety and Depression Scale) and fatigue (Functional Assessment of Chronic Illness Therapy—Fatigue)) assessed before and after the programme. Furthermore, cyber sickness (Simulator Sickness Questionnaire) at each session, VR usability (System Usability Scale—third session) and patient satisfaction to the programme will also be assessed.Ethics and disseminationThe study was approved by the local ethics committee (French Ouest II personal protection committee no. ID RCB: 2023-A02163-42) on January 2024. It was validated by the review board of the participating center. An individual participant data-sharing statement is not planned. Written informed consent will be obtained from all patients before any study procedure. The results of this pilot study will be disseminated through peer-reviewed journals and conference presentations.Trial registration numberNCT06267014. STRENGTHS AND LIMITATIONS OF THIS STUDY This cognitive rehabilitation programme combines virtual reality, cognitive training and psychoeducation. This cognitive rehabilitation programme combines virtual reality, cognitive training and psychoeducation. Virtual reality-based cognitive rehabilitation offers a controlled, reproducible and immersive training environment in an ecological context. Virtual reality-based cognitive rehabilitation offers a controlled, reproducible and immersive training environment in an ecological context. The study addresses a gap in the literature through the development of a programme specifically designed to support employment in patients with breast cancer with cancer-related cognitive impairment. The study addresses a gap in the literature through the development of a programme specifically designed to support employment in patients with breast cancer with cancer-related cognitive impairment. This is a single-center study with a limited sample size, which may limit the generalisability of the findings. This is a single-center study with a limited sample size, which may limit the generalisability of the findings. Introduction Several studies have shown the impact of adjuvant cancer treatments on cognition, particularly chemotherapy. These cognitive impairments, referred to as cancer-related cognitive impairment (CRCI), mostly occur after the completion of adjuvant chemotherapy.1 Their presence is an increasing concern in the context of longer life expectancy, which now requires consideration of ‘life after cancer’. This phenomenon has been primarily studied in patients with breast cancer who have received adjuvant chemotherapy, with impairment mainly in memory, executive functions, processing speed and attention.1 2 Postchemotherapy cognitive impairment has been observed in 15–25% of patients with breast cancer.3 These cognitive alterations also appear to be induced by new targeted therapies, and even by immunotherapy, which are becoming major treatments in oncology.46 In addition to other treatment-related side effects, cognitive difficulties negatively affect patients’ quality of life.7 8 These issues can hinder return to work9 and lead to reduced self-confidence in professional or social environments.78 1012 Many patients reported that these difficulties impacted their work and required compensatory strategies to perform tasks.12 Several studies have also shown a detrimental link between cognitive complaints and professional activity (notably work ability) among women treated for breast cancer.13 14 It is therefore particularly important to assess and manage these impairments, especially to facilitate employment. Results from a large national survey (n=1610) showed that 75% of participants (the majority being women treated for breast cancer) reported cognitive complaints related to cancer treatments.15 Among these participants, 75% would have liked to receive specific care, preferably cognitive training (72%). Additionally, cognitive difficulties significantly impacted return to work for 76% of participants with cognitive complaints. Despite the high number of patients with breast cancer reporting cognitive difficulties after treatment and expressing a desire for care, there is currently no validated, specific intervention available. To date, some physical and cognitive rehabilitation techniques (including cognitive training and psychoeducation) have shown efficacy in reducing cognitive complaints in patients suffering from CRCI.1618 Despite these encouraging early results, there are still no available data on the benefit of cognitive rehabilitation programmes specifically aimed at facilitating employment and no training programme dedicated to resuming professional activity has yet been developed to improve CRCI.19 Outside the cancer field, extensive evidence shows that training based on simple visual discrimination and rapid decision-making tasks can enhance processing speed and, in some cases, produce meaningful transfer to everyday functioning.20 21 Furthermore, systematic reviews confirm that improvements can generalise to broader cognitive domains.22 In addition, processing speed difficulties can impact return to work of patients with breast cancer,9 hence the interest to train it. Virtual reality (VR) is a scientific field of computing and a set of so-called ‘immersive’ technologies that allow a user to be immersed in a synthetic 3D environment, simulated in real time by a computer. VR has also been successfully used for many years in the medical field, offering ecological situations, particularly for neurorehabilitation for acute and neurodegenerative conditions.23 Indeed, VR offers several advantages for cognitive rehabilitation, including the ability to provide a controlled, reproducible and immersive environment training in an ecological context (ie, a simulated environment that closely replicates everyday settings). It enables the creation of a standardised environment across participants while still allowing the virtual environment to be adjusted according to predetermined parameters—such as difficulty level—to meet individual patient needs.24 25 Furthermore, VR ecological environment emphasises training cognitive functions in contexts that closely resemble real-world environments and everyday task demands.25 This approach is grounded in evidence showing that interventions with high ecological validity improve generalisation and transfer of skills to real-world situations19 26 and appear to have a positive impact on cognitive rehabilitation and professional reintegration. However, in oncology, VR has not yet been used to stimulate cognition and support the resumption of professional activity in patients with CRCI.19 In this context, we propose the Cog-VR (Cognition - Virtual Reality) pilot study to assess patient adherence to a VR-based cognitive rehabilitation programme. This programme is designed to train cognitive functions in patients with breast cancer who report cognitive difficulties following cancer and its treatments, with the ultimate goal of supporting their return or maintenance of employment. Methods and analysis Study design The Cog-RV pilot study is an ongoing prospective, single-center, single-arm interventional trial (figure 1). All the participants will be assessed at inclusion—baseline (T0), at the end of the 6-week rehabilitation programme (T1). Standard Protocol Items: Recommendations for Interventional Trials schedule of enrolment, interventions and assessment. Participants Inclusion criteria are women over 18 years of age diagnosed with breast cancer and who have received adjuvant chemotherapy (patients on maintenance treatments such as trastuzumab or hormone therapy are eligible), with no more than 2-year interval since completion of adjuvant treatments; reporting cognitive complaints at inclusion (ie, responding ‘yes’ to the question: “Since your cancer treatments, have you experienced difficulties with memory, concentration, etc?”); and either planning to return to work or having resumed employment during the past year. Exclusion criteria include presence of medical conditions that impair the ability to understand, follow or comply with study procedures; diagnosis of personality disorders or psychiatric pathology; legal incapacity (deprivation of liberty or guardianship) and pregnant women. Study procedures Recruitment Recruitment will be conducted between May 2024 and May 2026 in the comprehensive cancer center François Baclesse (Caen, France). The Cog-VR pilot study will be proposed to eligible patients with breast cancer reporting cognitive complaints, planning to return to work or having resumed employment in the past year and wishing to start cognitive rehabilitation. An information note and informed consent form will be provided. Patients will have as much time as they wish to consider participation. After providing signed informed consent before any study procedure, patients are enrolled if they meet all eligibility criteria (figure 1). Inclusion will be recorded in the study’s dedicated database. Each patient will be assigned a unique identification number to be used throughout the study. The VR cognitive rehabilitation programme must begin within 15 days of inclusion. Intervention The study will be offered to eligible patients with cognitive complaints wishing to begin a cognitive rehabilitation programme. Cognitive rehabilitation programme content The cognitive rehabilitation programme, based on the Schuurs and Green approach,27 has been adapted for this study to integrate VR and was developed in collaboration with the French INRIA «Hybrid» team (Université de Rennes, UMR IRISA). It consists of six weekly individual sessions conducted onsite at the François Baclesse Center under the supervision of a neuropsychologist. Each session, lasting approximately 1 hour, includes 20 min of cognitive training exercises and 15 min of psychoeducation time. For study participants, the programme is supplemented with a VR component, with each session incorporating a 10–15 min VR immersion. Cognitive training using the online PRESCO programme from HAPPYNeuron, developed by French neurologist B Croisile, is available in 11 languages, allowing international comparison. It has been used mainly in psychiatric clinical studies and in studies with patients with breast cancer.18 28 This home-based programme covers 12 cognitive domains, especially attention, memory, executive functions and processing speed—the most affected by cancer treatments.1 2 It includes 41 gamified cognitive training exercises across nine difficulty levels. Instructions and demonstrations precede each exercise, with a test to ensure understanding. All participants start each exercise at level 1 (very easy). Completing two exercises at the same level advances the patient to the next level. Feedback is given after each exercise to encourage or congratulate. Progress is maintained across sessions. Psychoeducation sessions starting with an introduction to cognition and factors affecting cognitive functioning, followed by focused sessions on specific cognitive functions (memory, executive functions, attention) and strategies to improve daily cognition. VR session details The VR programme, developed specifically for this study, simulates a professional-like environment involving tasks such as event planning and file sorting (figures 2–4). It takes place in a realistic 3D neighbourhood association setting, designed according to best practices for VR headset use. Screenshot of the virtual environment during the sorting task. Screenshot of the virtual environment during the planification task. Screenshot of the virtual environment during the prospective memory task. Each programme session includes a 10–15 min VR immersion, along with time before and after the immersion to discuss with the neuropsychologist, who explains the tasks and collects patient feedback. The tasks are intended to train executive functions (eg, planning), attention, memory and processing speed—the cognitive domains most frequently impaired by cancer treatments. During the first VR session, a familiarisation phase is implemented so that the patient can become familiar with the equipment and its use. The familiarisation environment includes very short versions of sorting, planning and prospective memory tasks. During each VR session, patients are asked to complete three tasks in a fixed sequence: a sorting task, a planning task and a prospective memory task. The level of difficulty is designed to increase progressively, with more items to process, exceptions introduced into the sorting rules and the addition of auditory distractions. The virtual environment automatically records several measures during each session, including the selected difficulty level, the time required to complete each task, the success rate and the number of times the instructions are consulted. Instructions for each task are displayed on whiteboards located outside the patient’s field of view, which can be consulted at any time if needed. Throughout the VR session, the patient sits on a chair. To move around, the patient uses a button on the controller that allows her to teleport to the target location. The patient is informed that she can interrupt the session at any time if she feels uncomfortable. In the sorting task (figure 2), the patient is presented with a set of cards and boxes into which she must sort the cards according to the rules provided. The cards may represent neighbourhood association membership records or bills. For example, each card may correspond to an association member, and the participant must quickly sort them into boxes according to their month of registration (figure 2). In the planning task (figure 3), the patient is given a blank monthly calendar and sticky notes representing events must be scheduled. Each event comes with its own set of constraints, such as purpose, reserved room, day of the week, time of day or deadline. Finally, for the prospective memory task (figure 4), the patient continues sorting cards as in the previous task while also performing additional actions triggered by environmental (event-based task). For example, she may sort bills by purchase month, place the ‘URGENT’ card aside when the phone rings and mail a package placed on her left after 60 s (time-based task, figure 4). Withdrawal from study Patients may discontinue participation in the study programme, whatever the reason, at any time. The data already collected during the search can be kept and exploited unless the patient opposes it. Whatever the number of sessions performed, any patient who prematurely withdraws from the study programme will be asked to perform the final assessment. Data collection Patients will be assessed up to the end of the study 6-week intervention, as detailed in figure 1 and table 1. Assessments include the evaluation of cognitive performances and the completion of standardised self-questionnaires. Data entry and handling are based on an electronic case report form. Patients are identified with a unique participant number. Access to the study database is restricted and secure. Table 1Overview of the Cog-RV study assessmentsAssessmentT0 (before intervention)Each weekly session of VRT1 (end of the 6-week intervention)Objective cognitive assessment Montreal Cognitive AssessmentXX RL/RI 16-item testXX Digit span (WAIS-IV)XX Trail Making TestXX Stroop testXX d2RXX Verbal fluencyXX Symbol search (WAIS-IV)XXPatient-reported outcomes FACT-Cog, FACIT-F, HADSXXVirtual reality-related questionnaires Simulator Sickness QuestionnaireX System Usability ScaleOnly at the third Satisfaction questionnaireXCog-RV, Cognition - Virtual Reality; D2R, Test of attention - revised; FACIT-F, Functional Assessment of Chronic Illness Therapy—Fatigue; FACT-Cog, Functional Assessment of Cancer Therapy—Cognitive Scale; HADS, Hospital Anxiety and Depression Scale; RL/RI 16-item test, French adaptation of the Free and Cued Selective Reminding Test; VR, virtual reality; WAIS-IV, Wechsler Adult Intelligence Scale 4th edition. Overview of the Cog-RV study assessments Cog-RV, Cognition - Virtual Reality; D2R, Test of attention - revised; FACIT-F, Functional Assessment of Chronic Illness Therapy—Fatigue; FACT-Cog, Functional Assessment of Cancer Therapy—Cognitive Scale; HADS, Hospital Anxiety and Depression Scale; RL/RI 16-item test, French adaptation of the Free and Cued Selective Reminding Test; VR, virtual reality; WAIS-IV, Wechsler Adult Intelligence Scale 4th edition. Study outcomes Primary outcomes The primary objective is to assess adherence to a VR-based cognitive rehabilitation programme in patients with breast cancer reporting cognitive complaints following cancer and its treatments. The programme consists of six VR weekly sessions, each lasting 10–15 min. Consistent with the commonly used definition of medication adherence (Medication Possession Ratio≥80%), adherence is defined as completing at least five of the six VR sessions. A VR session is considered complete if it lasts a minimum of 5 min. Secondary outcomes The secondary outcomes include assessment (table 1) of objective cognitive performance (executive, attentional, memory and processing speed functions assessed by a neuropsychologist using the following tests: Montreal Cognitive Assessment,29 Trail Making Test,30 Stroop,31 verbal fluency,32 d2R,33 RL/RI 16 items,34 digit spans,35 symbol search35) and subjective cognitive functioning (cognitive complaints assessed using the Functional Assessment of Cancer Therapy—Cognitive Scale (FACT-Cog) self-reported questionnaire).36 Patient-reported outcomes are also used to assess fatigue (Functional Assessment of Chronic Illness Therapy—Fatigue (FACIT-F))37 and anxiety and depression (Hospital Anxiety and Depression Scale (HADS)).38 Total duration assessment is around 1 hour and 30 min. This assessment is performed pre-intervention and post-intervention. The timeline for enrolment, intervention and assessment is presented in figure 1. After each weekly session of the programme, patients will complete the cyber sickness questionnaire39 to record possible adverse events (nausea, headaches, etc). The actual duration of each VR immersion session will be recorded; reasons for any missed sessions will be documented. After the third session, patients will evaluate VR usability using the System Usability Scale (F-SUS) questionnaire.40 After the 6-week VR-based cognitive rehabilitation programme, an evaluation will include patient satisfaction with the programme (virtual environment, number/duration of sessions, usefulness) via a specific questionnaire and cognitive evaluation using the same tools as baseline (objectives cognitive tests, FACT-Cog, FACIT-F and HADS). Statistical consideration Sample size The primary goal is to evaluate the adherence rate to the VR cognitive rehabilitation programme in patients with breast cancer after adjuvant therapy. A patient completing at least five out of six VR sessions, each lasting a minimum of 5 min, is defined as adherent to the programme. An adherence rate ≤60% (null hypothesis H0) is unsatisfactory; ≥85% (alternative hypothesis H1) is satisfactory. 20 evaluable patients are needed to reject H0 with 5% alpha risk and 80% power per Fleming design. At least 17 adherent patients among 20 evaluable ones will reject H0. To anticipate 10% of potential non-evaluable patients, the inclusion of 23 patients is planned. Statistical analysis Analysis population will include all patients who initiated at least one VR session. Adherence rate will be estimated with a 95% CI among the overall analysis population. In a descriptive intent, it will also be estimated while distinguishing patients planning to return to work and patients having resumed employment. The tolerance profile will describe adverse events related to VR headset use and programme participation (nausea, headaches, etc). Quantitative data from usability, satisfaction, cognitive complaints, fatigue, anxiety/depression and cognitive performance questionnaires will be summarised with means, SD, medians and ranges; qualitative data by frequencies and percentages. Cognitive complaints and objective cognitive scores at inclusion and programme end will be compared using the Wilcoxon Mann-Whitney test for paired data. Patient and public involvement Prior to the study conception and VR programme development, patients participating in the cognitive rehabilitation programme proposed as a supportive care as well as healthcare staff involved in identifying patients with cognitive complaints were asked to complete a survey regarding the development of a VR cognitive stimulation programme. Most of the responders (43 patients and 19 health professionals) considered virtual environments may be helpful for patients with cognitive difficulties for return to work. The majority of patients (80%) reported to be ready to use weekly a VR cognitive stimulation programme. The VR programme was developed considering the comments from patients and caregivers. Data monitoring and management The coordinating neuropsychologist will oversee systematic monitoring of both programme adherence and patient progress. Study staff will be responsible for supervising data collection and identifying protocol deviations. A data monitoring committee will not be required, as the study is deemed to pose minimal risk. A web-based data capture system will be used for inclusion, data collection and query management. The investigator will ensure that data are accurately recorded on the electronic Case Report Forms (eCRFs) in accordance with the trial protocol and related guidelines. The investigator is responsible for the accuracy, completeness and timely submission of the recorded data, as well as of the provision of answers to data queries according to the Clinical Study Agreement. The investigator will also be responsible for signing the completed eCRFs. A copy of the finalised eCRFs will be archived at the study site. Ethics and dissemination The study was approved by the local ethics committee (French Ouest II personal protection committee no. ID RCB: 2023-A02163-42). This trial is registered under the identifier NCT06267014 from September 2024 (https://clinicaltrials.gov/study/NCT06267014). The study is conducted in accordance with the ethical standards of the Helsinki Declaration. Informed consent will be obtained by healthcare providers (neuropsychologist, oncologist, nurse) from all individual participants before study entry and any study procedures. The results of this pilot study will be disseminated through peer-reviewed journals and conference presentations. Discussion This pilot study represents an essential first step towards implementing a multicenter randomised clinical trial to evaluate the benefits of the developed ecological VR-based cognitive rehabilitation programme to support employment in patients with breast cancer. Furthermore, this step will allow us to identify potential improvements and adjustments to the developed programme, assess patient adherence rates and determine whether adherence is sufficient to warrant proceeding with a study to assess the efficacy of the VR programme. The ultimate goal of this innovative research programme will be to implement and generalise, within the context of supportive care, an ecological, adapted and effective approach to address cognitive difficulties currently absent from supportive care. This should improve the return to work of patients suffering from cognitive difficulties after breast cancer.